Explore how cfDNA levels change around colorectal cancer surgery and their potential as non-invasive biomarkers for ...

The following is a summary of “Collagen turnover biomarkers to predict outcome of patients with biliary cancer,” published in ...

A new research paper was published in Oncotarget’s Volume 16 on January 21, 2025, titled “Assessment of cfDNA release dynamics during colorectal cancer surgery.” ...

Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal ...

and patients with elevated levels of carcinoembryonic antigen (CEA), a common cancer marker. Patients with the highest cfDNA levels were those with larger or more aggressive tumors, likely due to ...

[14] To evaluate biliary strictures of undetermined etiology, the efficacies of variable diagnostic impetuses such as tumor markers, radiological evaluations, endoscopic approaches and tissue ...

Biomarkers to assist in evaluating some cancers (tumor markers) have also been used for ... reactive protein (CRP), carcinoembryonic antigen (CEA), and alpha-1-antitrypsin. A 2018 study was ...

The different methylation patterns between Normal and Tumor were also quite evident (Figure s3B-C ... combine the cfDNA methylation model with clinically commonly used markers such as CEA and CA19-9.

and breast cancer was not statistically significant. ROC analysis verified that the AUC area of hsa_circ_0007507 in distinguishing GC patients from healthy donors was 0.832, which was higher than the ...